Terrance P. Coyne sold $1.6M of RPRX
EVP & CFO at Royalty Pharma plc. 34,791 shares at an average of $46.78, traded Mar 2, 2026, filed Mar 4, 2026.
Score components
- +22RoleCFO
- +25Trade size$1.6M at market
- +10Share of holdings soldSold 26% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.4%, 3m +16.4%, 6m +34.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001814876-26-000012, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: By TPC RP 2021, LLC10b5-1 | -22,487 | $46.67 | $1.0M | 109,177 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: By TPC RP 2021, LLC10b5-1 | -10,429 | $47.01 | $490k | 98,748 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: TPC RP EPA1 LLC10b5-1 | -1,292 | $46.67 | $60k | 46,344 | Mar 4, 2026 |
| Mar 2, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: TPC RP EPA1 LLC10b5-1 | -583 | $47.01 | $27k | 45,761 | Mar 4, 2026 |
Related signals
Other insiders at Royalty Pharma plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $236k 4,126 shares | -100% | |
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $239k 4,126 shares | -50% | |
| 43Moderate | Royalty Pharma plc | Christopher Hite EVP & Chairman, Partnering | $5.9M 100,000 shares | -27% | |
| 38Weak | Royalty Pharma plc | Christopher Hite EVP & Chairman, Partnering | $6.0M 100,000 shares | -21% | |
| 50Moderate | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $646k 11,002 shares | -100% | |
| 38Weak | Royalty Pharma plc | Christopher Hite EVP & Chairman, Partnering | $7.3M 130,000 shares | -23% | |
| 41Moderate | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $508k 9,099 shares | -100% | |
| 38Weak | Royalty Pharma plc | Christopher Hite EVP & Chairman, Partnering | $8.2M 150,000 shares | -21% | |
| 31Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $502k 9,098 shares | -50% | |
| 62Notable | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $3.5M 64,399 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.